Global Edge launches three healthcare brands in Middle East and showcases their product lines at Arab Health 2025
Reports show consumer interest on health, fitness, nutrition, appearance, sleep, and mindfulness is growing in the Middle East.
The three new brands will empower individuals to make informed decisions and choices for a healthier future.
UAE: GE Services & Trading (Global Edge) a leading company serving as a gateway for businesses to expand to the GCC and MENA region, unveiled three innovative international healthcare brands – SRW®, eimele™ and Theronomic™ – at the Arab Health 2025 to cater to the growing demands for natural and effective healthcare solutions in the UAE and the Middle East region.
This move is in line with the UAE's vision to advance healthcare under the 'Forward Society' pillar of 'We the UAE 2031 Vision,' which seeks to establish an integrated and accessible healthcare system, enhance quality of life, and promote future-ready healthcare solutions. Through SRW®, anti-aging products, eimele™ plant-based products, and Theronomic™ tribiotic supplements, Global Edge seeks to empower customers and enhance access to world-class products that support healthy lifestyles.
SRW® ' Science Research Wellness ' offers a range of anti-aging products backed by scientific research. These products harness the power of natural ingredients to protect, repair, and rejuvenate cells, promoting longevity and vitality.
With over 3.1 billion people worldwide struggling to maintain a balanced diet and up to 87 per cent failing to consume enough fruits and vegetables, eimele™ offers a range of plant-based solutions to address these nutritional gaps. The products are packed with phytonutrients, providing customers with essential nutrients, supporting optimal health, and ensuring healthier lifestyles.
Theronomic™ TRIBIOTIC ® Gut Shield provides a comprehensive solution to gut health. By combining prebiotic, probiotic, and postbiotic ingredients, this innovative formula supports a
balanced microbiome, ensuring targeted health benefits. Each capsule of this product contains 30 billion CFU from multiple strains to promote better digestive health and enhanced immune system function.
Karim Hwalla, Director at Global Edge, stated: 'We are delighted to bring these innovative healthcare brands to the Middle East market. At Global Edge, we have emerged as a driving force and trusted leader in distribution and market entry. We believe that navigating successful market entry hinges on thorough research, a solid strategy, and dependable partnerships - principles that are deeply ingrained in everything we do. By aligning these elements with a practical and transparent approach, we have ensured that the journey of these new brands into the Middle East market was smooth and effective, especially by targeting events like Arab Health 2025.'
'Strategic location and supportive business environment of countries like UAE in the region make it an ideal platform for global brands to expand their reach. With its open market economy, economic stability, and support for private sector entities, the country offers innumerable opportunities for businesses to thrive. Hence, we are proud to support the UAE's vision to establish a world-class healthcare system,' he added
A recent McKinsey research highlighted the growing consumer interest in overall wellness, with a particular focus on health, fitness, nutrition, appearance, sleep, and mindfulness. The research also emphasised that more people are expected to increase their purchases of both wellness products and services over the next year, particularly those that emphasise physical and mental health.
This increasing demand for wellness products and services aligns with the offerings of the three brands launched by Global Edge. By introducing these brands, Global Edge aims to contribute
to the Middle East's growing healthcare sector and empower individuals to make informed decisions and choices for a healthier future.
-Ends-
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
6 days ago
- Al Etihad
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
3 June 2025 14:30 ABU DHABI (ALETIHAD)M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood approach does not replace but rather complements routine cancer screenings, and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalised care.'Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." Source: Aletihad - Abu Dhabi
TECHx
31-05-2025
- TECHx
Starkey MEA Unveils Edge AI for Better Hearing Month
Home » Smart Sectors » Healthcare » Starkey MEA Unveils Edge AI for Better Hearing Month Starkey MEA has announced its most advanced hearing solution to date is Edge AI. The launch is part of its ongoing campaign to promote hearing health awareness across the Middle East during Better Hearing Month. Edge AI is designed to replicate how the human brain processes sound. It performs up to 80 million personalized hearing adjustments per hour. This helps users stay connected, confident, and comfortable in any setting. At the core of the device is Starkey's G2 Neuro Processor. It features six times more transistors, ten times more memory, and four times faster processing than its predecessor. As a result, Edge AI can automatically adapt to complex sound environments. Whether it's a majlis in the UAE, a busy street in Jeddah, or a mall in Kuwait City, the device ensures real-time auditory clarity. Giscard Bechara, Regional Director, MEA, Starkey Laboratories Inc., stated that Edge AI is more than a hearing aid. He called it 'a technological breakthrough designed for real life.' He also emphasized the importance of early diagnosis and preventive check-ups for better hearing. Edge AI includes features that enhance connectivity, wellness, and convenience: Bluetooth LE Audio and Auracast™ broadcast for efficient streaming StarLink Edge TV Streamer, 60% smaller than before Select waterproof models offering up to 51 hours of battery life The device also integrates Neuro Sound Technology 2.0. This provides 30% more accurate speech detection in noisy environments. Dr. Mohamed Ali Eltom, Chairman of the International Diabetes Federation (MENA region), shared his experience. He reported that Edge AI restored his ability to engage in both professional and social settings. He described the device as a 'lifeline' for people who rely on communication. Additionally, Edge AI supports a holistic approach to hearing care. It includes sensor-driven balance assessments, fall detection alerts, and smartwatch integration via the My Starkey app. Users can manage hearing settings and track wellness on the go. Starkey MEA revealed that hearing loss is increasing across the region. Factors include exposure to prolonged noise and an ageing population. The company is working with audiologists and clinics to raise awareness, encourage early screening, and offer access to its latest technology during Better Hearing Month. Bechara added that better hearing leads to better living. He called Edge AI the company's most powerful solution and urged the public to take the first step toward hearing health.
Arabian Post
21-05-2025
- Arabian Post
Uni-Bio Science Group Receives NMPA Approval for 金因康® (Diquafosol Sodium Eye Drops), Advancing Dry Eye Syndrome Treatment in China
HONG KONG SAR – EQS Newswire – 21 May 2025 – Uni-Bio Science Group Limited (the 'Company', together with its subsidiaries, the 'Group') proudly announces that its new ophthalmology product, 金因康(Diquafosol Sodium Eye Drops), has received marketing approval from the China National Medical Products Administration (NMPA) [Approval Number: 國藥准字H20254149]. This milestone strengthens the Group's portfolio in ophthalmology, addressing the growing demand for innovative treatments in China's dry eye syndrome market, which affects an estimated 360 million individuals. As the Group's second ophthalmology drug following GeneSoft®, 金因康® addresses the underlying causes of dry eye syndrome by activating P2Y2 receptors to stimulate tear fluid and mucin secretion. It offers: Improved tear layer normalization and corneal epithelial repair. Treatment for patients with dry eye accompanied by abnormal tear-associated corneal epithelial defects. A next-generation option for more effective and patient-friendly care. China's dry eye syndrome market is projected to surpass RMB 42 billion by 2030, growing at a CAGR of 28.4%, driven by increased screen time and evolving lifestyles. 金因康® is well-positioned to capture this growing demand with its proven efficacy and safety, widely recognized since the originator launched in Japan in 2010. ADVERTISEMENT To ensure rapid market penetration, the Group has expanded its sales force and integrated resources across hospitals, pharmacies, and e-commerce platforms. Strategic partnerships with API suppliers have secured high-quality raw materials at competitive costs, further enhancing 金因康®'s affordability and market competitiveness. Looking ahead, Uni-Bio Science Group will continue to focus on clinical needs and invest in R&D to expand its ophthalmic drug pipeline. With over 20 years of technological expertise, the Group is committed to delivering high-quality medical solutions, raising the standards of ophthalmic care, and solidifying its leadership in China's growing ophthalmology market. Hashtag: #Uni-BioScience The issuer is solely responsible for the content of this announcement. About Uni-Bio Science Group Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and sales of pharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has three GMP manufacturing bases in Beijing, Dongguan and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology. Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690. About 金因康® Diquafosol Sodium Eye Drops are a medication for treating dry eye disease and are suitable for patients diagnosed with dry eye accompanied by abnormal tear-associated corneal epithelial defects. Diquafosol Sodium represents the next generation of dry eye medication, offering cutting-edge therapy through its novel mechanism as a P2Y2 receptor agonist, stimulating tear and mucin secretion. This addresses the underlying causes of dry eye syndrome, normalizing the tear layer and improving corneal epithelial damage.
